Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined the dissociation rates of these INIs with integrase (IN)-DNA complexes containing a broad panel of IN proteins, including IN substitutions corresponding to signature RAL and ELV resistance mutations. DTG dissociates slowly from a wild-type IN-DNA complex at 37°C with an off-rate of 2.7 × 10 −6 s −1 and a dissociative half-life ( t 1/2 ) of 71 h, significantly longer than the half-lives for RAL (8.8 h) and ELV (2.7 h). Prolonged binding ( t 1/2 , at least 5 h) was observed for DTG with IN-DNA complexes containing E92, Y143, Q148, and N155 substitutions. The addition of a second substitution to either Q148 or N155 typically resulted in an increase in the off-rate compared to that with the single substitution. For all of the IN substitutions tested, the off-rate of DTG from IN-DNA complexes was significantly slower (from 5 to 40 times slower) than the off-rate of RAL or ELV. These data are consistent with the potential for DTG to have a higher genetic barrier to resistance, provide evidence that the INI off-rate may be an important component of the mechanism of INI resistance, and suggest that the slow dissociation of DTG may contribute to its distinctive resistance profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the dissociation half-times of dolutegravir and bictegravir from the wild-type HIV-1 intasome were reported to be ~100 and 160 h, respectively164,165.”
From Structure and function of retroviral integrase (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complete nucleotide sequence of the AIDS virus, HTLV-III
Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A., Baumeister, K., et al. (1985) · Nature · doi:10.1038/313277a0 · Cited by 2,245 · cited 1×
“to make mutations in the wild type HIV-1 BH10 IN sequence (41).”
BackgroundDrug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131 · cited 1×
“Since INI binding generates nonreplicative forms of unintegrated viral cDNA, such as 2 long terminal repeats (27), there is less opportunity for the virus to undergo further rounds of replication which can generate additional mutations and thereby VOL.”
BackgroundRaltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691 · cited 1×
“21, 30, 40, 43, 47) and in clinical studies (5, 35, 36, 45).”
Retroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509 · cited 2×
“For RAL, two main pathways for resistance involve signature mutations which are initially observed at amino acids Q148 and N155 and are almost invariably found with secondary mutations which may increase resistance and impact viral fitness and catalytic efficiency (5, 11, 18, 38, 40).”
BackgroundMarkowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408 · cited 1×
“21, 30, 40, 43, 47) and in clinical studies (5, 35, 36, 45).”
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Self-citationShimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010246107 · Cited by 305 · cited 1×
“The crystal structures of prototype foamy virus (PFV) IN in complex with DNA and RAL, ELV, (24), or DTG (25) and HIV-1 IN structural modeling studies (8, 9) provide insight into INI binding modes and how substitutions in the active site could impact INI binding.”
Background
Research works printed but not linked: 9
- 8. DeAnda F., Hattori K., Yoshinaga T., Kawasuji T., Underwood M. R. 2010. Structural models of HIV-1 integrase and DNA in complex with S/GSK1349572, raltegravir, or elvitegravir: structure-based rationale for INI resistance profiles. Antiviral Ther. 15(Suppl. 2):A73 [Google Scholar]
- 9. DeAnda F., et al. 2010. Structural rationale for slow S/GSK1349572 dissociation from wild type (WT) and raltegravir (RAL) resistant HIV-1 integrase (IN), abstr. H-1166. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother American Society for Microbiology, Washington, DC [Google Scholar]
- 10. DeJesus E., et al. 2007. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137), abstr. TUPEB032. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention International AIDS Society, Geneva, Switzerland [Google Scholar]
- 13. Dicker I. B., et al. 2011. Longer integrase inhibitor dissociation half-lives induce persistent anti-HIV effects in cell culture, abstr. 521. Abstr. 18th Conf. Retrovir. Opportunistic Infect [Google Scholar]
- 23. Grobler J. A., et al. 2009. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors, abstr. O-10. Abstr. 10th Int. Workshop Clin. Pharmacol. HIV Ther. [Google Scholar]
- 28. Hluhanich R., et al. 2010. HIV integrase inhibitors (INIs) do not exert a post-antibiotic effect (PAE) despite slow dissociation from IN-DNA complexes in vitro, abstr. H-930. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother American Society for Microbiology, Washington, DC [Google Scholar]
- 29. Johns B., et al. 2010. The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile, abstr. 55. Abstr. 17th Conf. Retrovir. Opportunistic Infect. [Google Scholar]
- 46. Underwood M. R., Johns B., Sato A., Fujiwara T., Spreen W. 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy, abstr. WEPEA098. Abstr. 5th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention International AIDS Society, Geneva, Switzerland [Google Scholar]
- 48. Yoshinaga T., Kanamori-Koyama M., Seki T., Sato A., Fujiwara T. 2010. Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. Antivir. Ther. 15(Suppl. 2):A12 [Google Scholar] Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)
Cited by
Items 201–258 of 258
In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs
Hinay, A. A., Kanai, K., Tsuneki-Tokunaga, A., Komatsu, M., Telan, E. O., & Kageyama, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315380 · Cited by 2
Parczewski, M. (2014) · HIV & AIDS Review · doi:10.1016/j.hivar.2014.06.002 · Cited by 2
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers
Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., Khoo, S., Owen, A., & Boffito, M. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky571 · Cited by 2
DOLUTEGRAVIR efficacy in HIV infected patients
Dumitru, I. M., Cernat, R. C., & Rugină, S. (2015) · Ars medica tomitana · doi:10.1515/arsm-2015-0019 · Cited by 2
“demonstrated that the highest genetic barrier of DTG may be attributed to its significantly slower rate of dissociation from the integrase enzyme in viruses that are either wild type or contain the N155, Q148 or Y143 mutations [23].”
BackgroundPrevalência de Efeitos Neuropsiquiátricos em Doentes com Infecção VIH sob Dolutegravir
de Morais, R. A. A. (2019) · Medicina Interna · doi:10.24950/rspmi/original/64/1/2019 · Cited by 2
Retroviral Integrase Structure and DNA Recombination Mechanism
Engelman, A., & Cherepanov, P. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch44 · Cited by 2
Non-integrase mechanisms for dolutegravir resistance
Engelman, A. (2026) · Retrovirology · doi:10.1186/s12977-026-00678-5 · Cited by 1
“…of first generation INSTIs RAL and elvitegravir (EVG) from IN-viral DNA complexes were ~ 9 h and 3 h, respectively, second-generation compounds DTG and bictegravir (BIC) remained associated for significantly longer periods, dissociating at half-lives of ~ 71–96 h and 163 h, respectively [69, 70].”
Saccoliti, F., Patacchini, E., Cara, E., Zarbo, L., Messore, A., Albano, A., Ruggieri, G., Madia, V. N., Scipione, L., Costi, R., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70428 · Cited by 1
Patel, P. A. (2013) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Development of an HIV‐1 integrase genotyping assay for HIV‐1 subtype AE
Liu, Y., Margot, N., Kitrinos, K. M., & Callebaut, C. (2018) · Journal of Medical Virology · doi:10.1002/jmv.25376 · Cited by 1
Enoki, Y., Suzuki, N., Ito, M., Uchiyama, E., Kishi, N., Ito, C., Kitahiro, Y., Sakamoto, K., Taguchi, K., Yokoyama, Y., et al. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13330 · Cited by 1
Experiencia preliminar de pacientes pediátricos con infección VIH en tratamiento con Dolutegravir
López, M. G., & Nexans-Navas, M. (2019) · Boletín Venezolano de Infectología · Cited by 1
New Antiretroviral Agents for HIV Infection
Fong, I. W. (2023) · Emerging infectious diseases of the 21st century · doi:10.1007/978-3-031-26078-0_12 · Cited by 1
Abé, E., Landman, R., Assoumou, L., Amat, K. K. A., Lambert-Niclot, S., Bellet, J., Gibowski, S., Girard, P., Morand‐Joubert, L., de Truchis, P., et al. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae112 · Cited by 1
Resistencias a antirretrovirales: Nuevos métodos de detección, nuevas aplicaciones
Fernández-Caballero, J. Á. (2017) · Institutional Repository of the University of Granada (University of Granada) · Cited by 1
Kawuma, A. (2023) · Open University of Cape Town (University of Cape Town) · Cited by 1
Darazi, P. E. (2021) · theses.fr (ABES) · doi:10.70675/7bb07492ze915z4ca3z845fzba3bb62a3520 · Cited by 1
Biochemical, Structural, And Drug Design Studies Of Multi-Drug Resistant Hiv-1 Therapeutic Targets
Dewdney, T. G. (2013) · Human Biology · Cited by 1
Wainberg, M. A., Mésplède, T., & Raffi, F. (2014) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2014.01.008
Is Drug Resistance in First-Line Therapy against All Antiretroviral Agents Inevitable?
Wainberg, M. A. (2015) · Journal of Infectious Diseases and Therapy · doi:10.4172/2332-0877.1000208
“In addition, the R263K mutation only diminished this level of binding by about 50% ([13], unpublished data) and this is still longer than the dissociation half-life of EVG and RAL for the wild-type enzyme; this suggests that the development of low-level resistance against DTG in first-line therapy might not have adver…”
BackgroundHiv Integrase Mechanisms Of Resistance To Raltegravir, Elvitegravir, And Dolutegravir
Ross, K. T. (2015) · Human Biology
Acosta, E. P., Taiwo, B., & Eron, J. J. (2012) · AIDS · doi:10.1097/qad.0b013e32834e89ef
HIV: Treatment and Comorbidity
Rokx, C. (2016) · RePub (Erasmus University Rotterdam)
HIV-1 Integrase Inhibitors Resistance: Update of the Current Literature
Maraolo, A. E. (2017) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-017-0113-0
HIV-1 Resistance to Integrase Inhibitors
Han, Y.-S., Mésplède, T., & Wainberg, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_37
Amadori, C. (2016) · theses.fr (ABES) · doi:10.70675/2da75a32z2820z4ceaz8909zee47e88e36ee
“Les traitements actuels basés sur l’utilisation d’INSTIs, notamment ceux combinant le DTG, montrent une faible toxicité et sont très efficaces pour supprimer la réplication du VIH-1 chez les patients traités [304].”
BackgroundInfluentialIsaacs, D. (2021) · University of the Western Cape Electronic Theses and Dissertations Repository (University of the Western Cape)
Hinay, A. A., Kanai, K., Tsuneki-Tokunaga, A., Komatsu, M., Telan, E. O., & Kageyama, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1879721/v1
Mésplède, T., Raffi, F., & Wainberg, M. A. (2023) · Actualizaciones en Sida e Infectología · doi:10.52226/revista.v22i85.264
“Estos hallazgos podrían deberse en gran medida al hecho de que DTG tiene la capacidad de unirse a la enzima inte-grasa por un tiempo extremadamente prolongado que excede en varias veces la capacidad de RAL o de EVG de lograr una unión similar (13).”
BackgroundGriesel, R., Banda, C. G., Zhao, Y., Omar, Z., Wiesner, L., Meintjes, G., Sinxadi, P., & Maartens, G. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003402
“Dolutegravir has a long dissociative half-life of 71 hours from integrase, 19 which should mitigate against the selection of dolutegravir resistance with short periods of low trough concentrations.”
BackgroundSimplified antiretroviral treatment regimens: the dolutegravir revolution
Makiwane, M., Mothata-Motswaledi, K., & Osuch, E. (2024) · South African General Practitioner · doi:10.36303/sagp.0276
Pallanza, M., Thoueille, P., Briki, M., Saldanha, S. A., Cavassini, M. L., & Marzolini, C. (2025) · Antiviral Therapy · doi:10.1177/13596535251335080
“13 Therapeutic drug monitoring can guide the need for twice daily dosing dolutegravir in presence of strong inducers.”
Min, S., Kim, S. H., Underwood, M., Wynne, B., & Spreen, W. (2025) · Wiley eBooks · doi:10.1002/9783527845088.ch03
Self-citationDickinson, L., Else, L., Venter, F., Boffito, M., Brand, R. M., Waitt, C. J., Hill, A. M., & Khoo, S. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf445
SeyedAlinaghi, S., Afsahi, A. M., Moradi, A., Parmoon, Z., Habibi, P., Mirzapour, P., Dashti, M., Ghasemzadeh, A., Karimi, E., Sanaati, F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26632959
Santos, J. R., & de Medicina, U. A. D. B. D. (2014) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Looking at HIV-1 transmission in Quebec through a phylogenetic lens
Cuadra-Foy, E. (2020) · eScholarship@McGill (McGill) · doi:10.82308/34829
Mesenteric Lymphatic Targeting of Antiretroviral agents for Improved Treatment of HIV/AIDS
Chu, Y. (2023) · Nottingham ePrints (University of Nottingham)
Wares, M. (2014) · eScholarship@McGill (McGill) · doi:10.82308/46572
Kengo, A. (2025) · Open University of Cape Town (University of Cape Town)
タカイ ゾウショクノウ オ モツ HIV ブンリ カブ ノ コウ レトロウイルスヤク ニ タイスル サイボウ バイヨウ ニ オケル カンジュセイ
Hinay, A. A., & ヒナイ, ア. ジ. ア. (2023) · Institutional Repositories DataBase (IRDB)
Caractérisation des voies d’échappement aux inhibiteurs d’intégrase du VIH-1
Thierry, E. (2015) · theses.fr (ABES) · doi:10.70675/602eaec1z5d9az4bb2za08dz10755e91efc2
HIV-1 Integrase During the Time: History of Drugs and Effort for the New Inhibitors’ Identification
Esposito, F., Saccoliti, F., Patacchini, E., & Santo, R. D. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_180
HIV-1 can undergo Env-independent retrotransposon-like activityPreprint
Matsumura, S., Amesimeku, W. A. O., Rajib, S. A., Monde, N., Sasaki, H., Terasawa, H., Hossain, M. J., Sawa, T., Maeda, Y., Satou, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719790
Drug Discovery Targeting Viral Metalloenzymes
Li, B., Xu, H., Zhou, J., Tang, K., Liu, X., Yang, J., & Zhan, P. (2026) · Wiley eBooks · doi:10.1002/9783527848683.ch10
LaCourse, S. M., Govender, V., Moloantoa, T., anon, M., Varughese, L., Nonyane, B. A. S., Kim, S., Moodley, J., Beattie, T., Pretorius, L., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7543723
A TERAPIA ANTIRRETROVIRAL E AS CLASSES DE MEDICAMENTOS ANTI-HIV
de Siqueira, E. C., de França, J. A. A., & Doboszewski, B. D. (2026) · doi:10.66697/q25mxm12
BindingDB Entry 50006022: Inhibiting the HIV integration process: past, present, and the future.
BindingDB (2020) · UC San Diego · doi:10.7270/q2qc06gp
BindingDB Entry 50018529: Advances in the development of HIV integrase strand transfer inhibitors.
BindingDB (2024) · UC San Diego · doi:10.7270/q25143gj
Dosing HIV integrase inhibitors with enzyme inducers: Convenience vs . control?
Marzolini, C., & Khoo, S. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70900
Dolutegravir in HIV-1 infection: a guide to its use
McCormack, P. L. (2015) · Drugs & Therapy Perspectives · doi:10.1007/s40267-015-0226-9
“0001) more slowly than either raltegravir or elvitegravir [9], and was highly active in vitro against most HIV-1 strains that were resistant to raltegravir [10–12].”
Background
Metadata
- Authors
- Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., & Underwood, M. R.
- Affiliations
- GlaxoSmithKline, Research Triangle Park, North Carolina
- Shionogi (Japan) (JP)
- Corresponding author
- Underwood, Mark R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2011-10
- Volume
- 55
- Issue
- 10
- Pages
- 4552-4559
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3187001
- OpenAlex
- W2144255757
- Cited by
- 226
- References
- 39
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 11 · 2017: 19 · 2016: 16 · 2015: 32 · 2014: 27 · 2013: 23 · 2012: 17
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- dolutegravir, raltegravir, elvitegravir, HIV-1 integrase inhibitors, integrase inhibitor resistance, integrase-DNA complex, dissociation rate, dissociation rate constant, resistance mutations, resistance mechanisms
- MeSH terms
- Raltegravir Potassium, Dolutegravir, DNA, Viral, Genotype, Heterocyclic Compounds, 3-Ring, Mutation, Oxazines, Piperazines, Pyridones, Pyrrolidinones, Quinolones, HIV-1, DNA, Complementary, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.